Comparison of metabolic parameters during treatment for schizophrenia with olanzapine intramuscular long-acting injection versus olanzapine oral formulation

被引：0
|
作者：
Gulliver, A. [1 ]
McDonnell, D. P. [1 ]
Kryzhanovskaya, L. A. [1 ]
Zhao, F. [1 ]
Detke, H. C. [1 ]
Feldman, P. D. [1 ]
机构：
[1] Eli Lilly & Co, Lilly Res Labs, Indianapolis, IN 46285 USA
来源：
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY | 2008年 / 11卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：152 / 152
页数：1
相关论文
共 50 条
  • [1] Comparison of metabolic changes in patients with schizophrenia during randomized treatment with intramuscular olanzapine long-acting injection versus oral olanzapine
    McDonnell, David P.
    Kryzhanovskaya, Ludmila A.
    Zhao, Fangyi
    Detke, Holland C.
    Feldman, Peter D.
    HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL, 2011, 26 (06) : 422 - 433
  • [2] Comparison of metabolic changes in patients with schizophrenia during randomized treatment with intramuscular olanzapine long-acting injection versus oral olanzapine (vol 26, pg 422, 2011)
    McDonnell, D. P.
    Kryzhanovskaya, L. A.
    Zhao, F.
    Detke, H. C.
    Feldman, P. D.
    HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL, 2011, 26 (07) : 536 - 536
  • [3] Assessing the infrequent oral supplementation of olanzapine long-acting injection in the treatment of schizophrenia
    Ascher-Svanum, H.
    Peng, X.
    Montgomery, W.
    Faries, D. E.
    Lawson, A. H.
    Witte, M. M.
    Novick, D.
    Jemiai, N.
    Perrin, E.
    McDonnell, D. P.
    EUROPEAN PSYCHIATRY, 2011, 26 (05) : 313 - 319
  • [4] Olanzapine Long-Acting Injection A Review of its Use in the Treatment of Schizophrenia
    Frampton, James E.
    DRUGS, 2010, 70 (17) : 2289 - 2313
  • [5] Efficacy and safety of olanzapine long-acting injection for maintenance treatment of schizophrenia
    Detke, H.
    McDonnell, D.
    Kane, J.
    Naber, D.
    Sethuraman, G.
    Lin, D.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2008, 18 : S393 - S394
  • [6] Long-acting olanzapine versus long-acting risperidone for schizophrenia in Spain – a cost-effectiveness comparison
    Tatiana Dilla
    Jörgen Möller
    Paul O’Donohoe
    María Álvarez
    José A Sacristán
    Michael Happich
    Antje Tockhorn
    BMC Psychiatry, 14
  • [7] Long-acting olanzapine versus long-acting risperidone for schizophrenia in Spain - a cost-effectiveness comparison
    Dilla, Tatiana
    Moeller, Joergen
    O'Donohoe, Paul
    Alvarez, Maria
    Sacristan, Jose A.
    Happich, Michael
    Tockhorn, Antje
    BMC PSYCHIATRY, 2014, 14
  • [8] Comparison of Olanzapine Long-Acting Injection and Oral Olanzapine A 2-Year, Randomized, Open-Label Study in Outpatients With Schizophrenia
    Detke, Holland C.
    Weiden, Peter J.
    Llorca, Pierre-Michel
    Choukour, Moutaz
    Watson, Susan B.
    Brunner, Elizabeth
    Ascher-Svanum, Haya
    JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2014, 34 (04) : 426 - 434
  • [9] OPEN-LABEL COMPARISON OF OLANZAPINE LONG-ACTING INJECTION AND ORAL OLANZAPINE: A 2-YEAR, RANDOMIZED STUDY IN OUTPATIENTS WITH SCHIZOPHRENIA
    Detke, Holland C.
    Weiden, Peter J.
    Llorca, P. M.
    Choukour, M.
    Watson, Susan B.
    Brunner, E.
    Ascher-Svanum, H.
    SCHIZOPHRENIA BULLETIN, 2011, 37 : 300 - 300
  • [10] Olanzapine long-acting injection: Pharmacokinetic and dose correspondence data relative to oral olanzapine
    Gulliver, A.
    Detke, H. C.
    McDonnell, D. P.
    Bergstrom, R. F.
    Lin, D.
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2008, 11 : 152 - 153
12345